In just 12 months, the British national provider reports a savings of 300 million UK Pounds by encouraging providers across the UK to stop prescribing higher-priced branded drugs and switch to economical biosimilars. NHS slashed its Humira price tag by £110M alone by...
Tsinghua University, School of Medicine and led a study comparing the efficacy and safety of IBI303 and the originator drug adalimumab (Humira®) on ankylosing spondylitis (AS) patients. IBI303 is comparable and its launch by Innovent Biologics, Inc. is expected to...
The TrialSite Network includes many thousands of Hidradenitis Suppurativa patients eager for greater focus and investment, research, and breakthrough therapies for this debilitating disease impacting approximately 3.3 million in the United States. We have recently...
Samsung Bioepis Co. Ltd. reports that the U.S. FDA has approved HADLIMA™ (adalimumab-bwwd), a biosimilar referencing HUMIRA® (adalimumab) for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult...
Alvotech, whose drug candidate AVT02 is being developed as a biosimilar to adalimumab (Humira, AbbVie), enrolled the first patient in a clinical phase 3 study evaluating the product, the company recently announced in a press release. Adalimumab, a tumor necrosis...
A study from last year focusing on cost trends for tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis (RA) after the entry of new competition reveals disturbing trends: new biosimilar competition, long assumed to drive down pricing, does not lower drug...
